Answers are grounded in this paper and cite their sources.
Purpose: Currently, there is no clear consensus for long follow-up schedule after partial nephrectomy (PN) for T1 renal cell carcinoma (RCC) after more than 5 years. It is reasonable to stratify follow-up schedule based on tumor stage and histopathologic subtype. Here, we evaluated the time to recurrence and oncological outcomes during follow-up for T1 RCC categorized on histopathologic subtype at our institution to determine the optimal surveillance schedule after surgery. Material and Methods: We performed a retrospective analysis of PNs from 1997 to 2018 at the University of Rochester. The primary outcomes included time to recurrence; secondary outcomes were time to death (regardless of cause) and death from metastatic RCC. Demographic and clinical information were collected. Kaplan-Meier analysis was used to estimate the survival of each primary outcome in each histologic group. Cox proportional hazards model was used to study the association between the outcome and clinical stage, adjusting for the effects of age at surgery, recurrence rate, time to recurrence, age at recurrence, histopathology subtype, and margin status. Outcomes for those with clear cell (ccRCC), papillary, and chromophobe (chRCC) histopathologic subtypes were analyzed separately. Results: We identified 850 PNs at our institution with 537 patients having pT1 RCC on final pathology. The mean follow-up time was 63.5 months (maximum follow-up 136 months). A total of 28 patient had a recurrence. The median time to recurrence was 49 (1-3 IQR 28-65) months. Of the 28 patients who had recurrence, 7 patients (25%) had a recurrence after 5 years. For those patients who had recurrence after 5 years, the mean time to recurrence was 93.43 months (7.78 years). Significant differences were found in age at surgery, length of follow-up, recurrence rate, mortality rate, and cancer specific mortality between RCC subtypes and stage. Overall, recurrence for T1a tumors was 3% and for T1b tumors was 10%. Recurrence was associated with death (hazard risk 4.42, IC 95% [1.58-12.32], P = .0045). The presence of positive margins was not associated with recurrence or survival. Although there were significant differences in recurrence-free survival and overall survival for T1a vs T1b RCCs, these differences were not found between RCC histologic subtypes. Conclusions: From our retrospective data for T1 RCC tumors after PN, most recurrences occurred in patients with stage T1b cancer more than 3 years from the date of surgery. Overall survival and cancer-specific survival is excellent for those presenting for T1 RCC. Most mortality in this population is not caused by RCC; thus, it may be beneficial to have less frequent but longer surveillance for those presenting with sporadic T1 RCC.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: